Literature DB >> 23178210

Very early versus early disease: the evolving definition of the 'many faces' of systemic sclerosis.

Marco Matucci-Cerinic1, Silvia Bellando-Randone, Gemma Lepri, Cosimo Bruni, Serena Guiducci.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23178210     DOI： 10.1136/annrheumdis-2012-202295

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

Review 1.  Early systemic sclerosis-opportunities for treatment.

Authors:  Lazaros I Sakkas; Theodora Simopoulou; Christina Katsiari; Dimitrios Bogdanos; Ian C Chikanza
Journal:  Clin Rheumatol       Date:  2015-02-26       Impact factor: 2.980

2.  CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc).

Authors:  Gabriele Valentini; Antonella Riccardi; Serena Vettori; Rosaria Irace; Michele Iudici; Salvatore Tolone; Ludovico Docimo; Marialuisa Bocchino; Alessandro Sanduzzi; Domenico Cozzolino
Journal:  Clin Exp Med       Date:  2016-09-20       Impact factor: 3.984

3.  Systemic Sclerosis Trial Design Moving Forward.

Authors:  Sindhu R Johnson; Dinesh Khanna; Yannick Allanore; Marco Matucci-Cerinic; Daniel E Furst
Journal:  J Scleroderma Relat Disord       Date:  2018-01-23

Review 4.  Precursors to Systemic Sclerosis and Systemic Lupus Erythematosus: From Undifferentiated Connective Tissue Disease to the Development of Identifiable Connective Tissue Diseases.

Authors:  Leonardo Martin Calderon; Janet E Pope
Journal:  Front Immunol       Date:  2022-05-05       Impact factor: 8.786

5.  Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis.

Authors:  S Bellando-Randone; G Lepri; C Bruni; J Blagojevic; A Radicati; L Cometi; A De Paulis; M Matucci-Cerinic; S Guiducci
Journal:  Clin Rheumatol       Date:  2015-12-03       Impact factor: 2.980

6.  Application of the 2013 ACR/EULAR classification criteria for systemic sclerosis to patients with Raynaud's phenomenon.

Authors:  Jin-Su Park; Min-Chan Park; Jason Jungsik Song; Yong-Beom Park; Soo-Kon Lee; Sang-Won Lee
Journal:  Arthritis Res Ther       Date:  2015-03-22       Impact factor: 5.156

7.  Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.

Authors:  Veronika K Jaeger; Elina G Wirz; Yannick Allanore; Philipp Rossbach; Gabriela Riemekasten; Eric Hachulla; Oliver Distler; Paolo Airò; Patricia E Carreira; Alexandra Balbir Gurman; Mohammed Tikly; Serena Vettori; Nemanja Damjanov; Ulf Müller-Ladner; Jörg H W Distler; Mangtao Li; Ulrich A Walker
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

8.  Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial.

Authors:  Wieneke M T van den Hombergh; Brigit E Kersten; Hanneke K A Knaapen-Hans; Rogier M Thurlings; Peter M van der Kraan; Frank H J van den Hoogen; Jaap Fransen; Madelon C Vonk
Journal:  Trials       Date:  2018-08-22       Impact factor: 2.279

Review 9.  Predicting the Progression of Very Early Systemic Sclerosis: Current Insights.

Authors:  Chiara Bellocchi; Augustine Chung; Elizabeth R Volkmann
Journal:  Open Access Rheumatol       Date:  2022-09-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.